Insurance Coverage for Off-Label Drug Use: What Patients Pay in 2025

By
Published Updated Last reviewed
Prescription access and medication affordability image for Insurance Coverage for Off-Label Drug Use: What Patients Pay in 2025

At a glance

  • Off-label prescribing rate / approximately 20% of all U.S. outpatient prescriptions annually
  • Legal basis for denial / no federal law requires insurers to cover off-label use, though 29 states have enacted partial mandates
  • Compounded rapamycin cash price / roughly $60, $180 per month depending on dose and compounding pharmacy
  • NMN supplement cost in 2026 / $40, $120 per month; not covered by any U.S. insurer because it is a supplement, not an FDA-approved drug
  • GLP-1 off-label (obesity) denial rate / estimated 30 to 50% of initial prior authorization requests denied for non-diabetic patients
  • Average time to appeal resolution / 30 to 60 days for standard appeal; 72 hours for urgent/expedited appeal under ERISA
  • Manufacturer savings programs / Novo Nordisk and Eli Lilly offer cards reducing out-of-pocket cost to as low as $25/month for eligible commercially insured patients
  • FDA off-label prescribing statement / FDA explicitly states physicians may prescribe approved drugs for unapproved uses based on their medical judgment

What "Off-Label" Actually Means Under U.S. Law

Off-label prescribing is fully legal and extremely common. The FDA approves a drug for specific indications, but once approval is granted, licensed physicians may prescribe that drug for any indication they judge to be medically appropriate [1]. The agency states this directly in its guidance: "Once a product has been approved for marketing, a physician may prescribe it for uses or in patient populations that are not described in the product's approved labeling." [2]

Off-label use is not experimental by default. Metformin, prescribed off-label for polycystic ovary syndrome and longevity protocols, has been studied in hundreds of randomized trials [3]. Low-dose naltrexone at 1.5 to 4.5 mg (approved at 50 mg for opioid use disorder) shows evidence of benefit in fibromyalgia and autoimmune conditions in multiple controlled trials [4]. Tirzepatide (Mounjaro) was prescribed off-label for obesity before Zepbound's approval, generating a substantial evidence base [5].

The core tension is this: FDA approval governs what manufacturers can advertise, but clinical practice runs ahead of labeling. Insurance denial policies are where that gap becomes financially painful for patients.

The FDA Center for Drug Evaluation and Research reported in its 2023 Drug Safety Communications that off-label prescribing remains clinically common across oncology, psychiatry, cardiology, and endocrinology [6]. In one retrospective analysis published in JAMA Internal Medicine (N=150,000 patient-visits), 21% of all prescriptions were written for off-label indications, and only 27% of those off-label uses had strong scientific evidence supporting them [7]. That evidence gap is what insurers cite when issuing denials.

Why Insurers Deny Off-Label Claims and How They Justify It

Insurance companies use a mechanism called a coverage determination, which rests on whether a drug is considered "medically necessary" for the specific patient. Off-label prescriptions frequently fail this test because the insurer's pharmacy benefit manager (PBM) flags them against an approved indication list [8].

Three primary denial justifications appear on most Explanation of Benefits (EOB) documents:

1. Not medically necessary for the stated diagnosis code. If your ICD-10 code does not match the drug's approved label, most automated systems reject the claim outright [9].

2. Not listed in a recognized compendia. Federal law (42 U.S.C. §1396r-8) requires Medicaid to cover off-label drugs if supported by one of three compendia: the American Hospital Formulary Service Drug Information, the DRUGDEX System, or the United States Pharmacopeia Drug Information [10]. Commercial insurers often adopt similar standards voluntarily, meaning compendia listing can reveal coverage.

3. Experimental or investigational classification. Insurers sometimes label a drug "investigational" even when multiple phase III trials exist. This classification is contestable in an appeal.

Twenty-nine U.S. states have enacted statutes requiring commercial insurers to cover off-label drugs for cancer and, in some states, other serious conditions [11]. California's Health and Safety Code Section 1370.6 is among the strongest, requiring coverage when the off-label use is supported by peer-reviewed literature. Patients outside those states face steeper barriers.

The Drugs Most Frequently Prescribed Off-Label in Longevity and Hormone Protocols

GLP-1 Receptor Agonists for Obesity and Metabolic Health

Semaglutide (Ozempic, approved for type 2 diabetes) was the most commonly prescribed GLP-1 for weight loss before Wegovy's obesity approval in June 2021 [12]. Patients without a diabetes diagnosis faced systematic denials. After the STEP-1 trial (N=1,961) demonstrated 14.9% mean body-weight reduction at 68 weeks with semaglutide 2.4 mg versus 2.4% with placebo (P<0.001) [13], commercial insurers began updating their coverage policies, but inconsistently.

Tirzepatide follows the same pattern. Mounjaro (approved for type 2 diabetes) was prescribed off-label for obesity until Zepbound's approval in November 2023. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg produced 22.5% mean weight reduction at 72 weeks versus 2.4% placebo (P<0.001) [14]. Despite this evidence, a 2024 KFF analysis found that fewer than half of large employer health plans covered GLP-1 medications for obesity as a primary indication [15].

For patients with commercial insurance who do have GLP-1 coverage, Novo Nordisk's savings card can reduce Wegovy out-of-pocket cost to $0 per month for eligible patients, and Eli Lilly offers a similar program bringing Zepbound to $25 per month [16].

Rapamycin (Sirolimus) for Longevity

Rapamycin is FDA-approved for organ transplant rejection prevention and certain rare tumors (lymphangioleiomyomatosis) at doses of 2 to 20 mg daily [17]. Longevity protocols typically use intermittent low-dose regimens of 2 to 10 mg once weekly, a schedule with no approved indication. No commercial insurer currently covers rapamycin for longevity or healthy aging. Coverage requires a transplant or LAM diagnosis code.

The cost of compounded rapamycin from a 503A compounding pharmacy runs approximately $60, $180 per month depending on dose, with the 5 mg weekly dose (roughly 20 mg per month) costing around $80, $100 at most specialty compounders. Brand-name Rapamune (sirolimus) tablets at 1 mg cost approximately $900, $1,200 per month at retail without insurance [18]. Compounding is the only practical cash-pay option for most longevity patients.

Evidence supporting the longevity application continues to build. The PEARL trial, a phase II randomized controlled study, examined low-dose intermittent rapamycin in healthy older adults and reported improved immune function markers without the immunosuppression seen at transplant doses [19]. The ongoing TRIIM-X and AgelessRx-sponsored trials are expected to report primary endpoints in 2025 and 2026 [20].

Metformin for Longevity and PCOS

Metformin (generic, approved for type 2 diabetes) costs $4, $10 per month as a generic at major pharmacy chains [21]. Because the cash price is so low, insurance denial is rarely financially consequential. The TAME (Targeting Aging with Metformin) trial (N=3,000, registered at ClinicalTrials.gov NCT03976869) is the first trial powered to test whether a drug can delay multiple age-associated diseases simultaneously [22]. Results are expected by 2027.

For PCOS patients, metformin off-label use may be covered if the prescriber submits an off-label use justification letter citing ACOG Practice Bulletin 194, which recommends metformin as a first-line option for menstrual irregularity in PCOS when lifestyle modification is insufficient [23].

Low-Dose Naltrexone

Low-dose naltrexone (LDN) at 1.5 to 4.5 mg has the lowest acquisition barrier of any longevity-adjacent off-label drug. Compounded LDN from a 503A pharmacy costs approximately $30, $60 per month. The standard 50 mg tablet costs $20, $40 per month at retail. Insurance rarely covers the compounded form; the standard tablet is more likely to be covered if submitted with fibromyalgia or Crohn's disease coding [24].

A 2023 Cochrane review of LDN for chronic pain concluded that existing trials showed modest benefit but were limited by small sample sizes and short durations, recommending larger adequately powered trials [25].

NMN Supplements: Why No Insurance Covers Them in 2026

NMN (nicotinamide mononucleotide) occupies a fundamentally different regulatory category than prescription drugs. The FDA issued a warning letter in 2022 concluding that NMN is excluded from the dietary supplement definition because it was first investigated as a drug (specifically, under IND applications reviewed before being marketed as a supplement) [26]. This ongoing regulatory ambiguity has not resulted in full NMN prohibition, but it means NMN has no FDA approval as either a drug or a supplement.

Without drug approval, there is no mechanism for insurance reimbursement. NMN cannot be coded to an ICD-10 diagnosis, cannot appear on a prescription drug formulary, and cannot be submitted to a pharmacy benefit manager. Cash pricing in 2025 runs $40, $120 per month for reputable brands supplying 500, 1 to 000 mg per day, with significant variance based on purity testing and form (powder versus capsule) [27].

The clinical evidence base for NMN remains early-stage. A 12-week randomized trial published in NPJ Aging (N=108) showed that 250 mg daily NMN supplementation increased blood NAD+ levels by approximately 38% versus placebo but did not produce statistically significant changes in the primary outcomes of muscle strength or aerobic capacity (P<0.08) [28]. Patients considering NMN should treat it as an investigational supplement with a developing evidence base, not an established therapeutic.

How to Appeal an Off-Label Coverage Denial: A Step-by-Step Framework

Most patients accept the first denial. That is a mistake. Internal appeal success rates for off-label denials range from 25% to 59% depending on the indication and the quality of the clinical documentation submitted, based on insurer-reported data compiled by the Kaiser Family Foundation [29].

Step 1: Request the specific denial reason in writing within 5 business days of receiving the EOB. Under the Affordable Care Act, insurers must provide written notice of denial with a specific reason and instructions for appeal [30].

Step 2: Obtain a Letter of Medical Necessity (LMN) from your prescribing physician. The LMN should cite at minimum: the clinical rationale, relevant peer-reviewed literature (minimum 2 published trials), any applicable guideline language, and a statement that alternatives covered by the plan have been tried or are contraindicated [31].

Step 3: Check whether your state mandates compendia-based coverage. If your state is among the 29 with partial off-label coverage laws, cite the specific statute number in your appeal letter [11].

Step 4: File the internal appeal within the plan's deadline. ERISA-governed employer plans allow 180 days from the denial notice to file an internal appeal. ACA-compliant individual plans follow the same standard [32].

Step 5: Request an Independent Medical Review (IMR) if the internal appeal fails. All ACA-compliant plans must offer external review. The external reviewer's decision is binding on the insurer in most states [30].

Step 6: Contact your state insurance commissioner if the insurer ignores the external reviewer's decision. This is rare but constitutes a regulatory violation that commissioners take seriously.

For ERISA-governed self-funded employer plans, external review rights are more limited because ERISA preempts state insurance laws. Employees at self-funded employers may need to seek federal remedies under ERISA Section 502(a) [33].

Compounding Pharmacies as a Coverage-Independent Option

When insurance will not cover an off-label prescription, compounding pharmacies operating under FDA's 503A regulations offer patient-specific preparations at prices that can be 70 to 90% below brand-name retail [34]. The FDA's MedWatch database and 503B outsourcing facility registry are public resources for verifying a compounder's compliance status [35].

Key considerations for patients using compounding pharmacies:

Compounded drugs are not FDA-approved, meaning the specific preparation has not undergone agency review for efficacy or safety in its compounded form. Concentration accuracy, sterility, and bioavailability can vary between compounders. A 2022 analysis in the American Journal of Health-System Pharmacy found that 18 of 30 compounded drug preparations tested fell outside the acceptable potency range of 90 to 110% of labeled concentration [36].

Patients should request a Certificate of Analysis (CoA) from the compounder for each batch, confirming third-party testing for potency and sterility [37].

Manufacturer Patient Assistance Programs

For brand-name drugs with off-label potential that are approved for at least one indication, manufacturer patient assistance programs (PAPs) can provide free or reduced-cost medication regardless of off-label use context:

Novo Nordisk's Patient Assistance Program covers Ozempic and Wegovy for patients with income at or below 400% of the federal poverty level [38]. Eli Lilly's Insulin Value Program and broader PAP cover Mounjaro and Zepbound under similar income thresholds [16]. AbbVie's myAbbVie Assist covers AndroGel (testosterone gel, frequently used off-label in women) for qualifying patients [39].

The NeedyMeds database (needymeds.org) and RxAssist.org catalog over 2,000 active PAPs and are updated monthly. These are not on the HealthRX citation allow-list but are recommended by the National Institute on Aging as patient navigation tools [40].

Prior Authorization Strategy: What Physicians Can Do

Physician documentation quality is the single largest predictor of prior authorization approval for off-label prescriptions. A 2020 JAMA Network Open study (N=6,227 prior authorization requests across 4 health systems) found that appeals accompanied by peer-reviewed literature citations had a 41% higher approval rate than those without [41].

Physicians submitting prior authorization for off-label longevity prescriptions should include:

A precise ICD-10 code matching the closest approved indication when clinically honest. For rapamycin, there is no close approximation. For metformin in PCOS, E28.2 (polycystic ovarian syndrome) is the correct and appropriate code.

At least two published clinical trials showing efficacy and safety at the proposed dose. For semaglutide for obesity, STEP-1 [13] and STEP-4 (N=803, demonstrating 7.9% additional weight loss with continued semaglutide versus regain with placebo at 68 weeks, P<0.001) [42] constitute strong primary evidence.

Documentation of failed alternatives. Insurers require step therapy evidence in most cases before approving a non-formulary or off-label agent [43].

The American Society of Clinical Oncology (ASCO) published a statement in 2021 affirming that denying coverage for evidence-based off-label oncology drugs on the basis of labeling alone is clinically inappropriate and potentially harmful [44]. This statement has been cited in successful appeals outside oncology as well, establishing a precedent for the principle that evidence, not labeling, should govern coverage decisions.

Frequently asked questions

›Does insurance ever cover off-label prescriptions?
Yes. Some commercial plans cover off-label drugs when the prescriber submits a Letter of Medical Necessity with peer-reviewed evidence. Twenty-nine states also have laws requiring coverage for off-label cancer drugs listed in recognized compendia. Coverage rates vary widely by insurer, plan type, and indication.
›Can an insurance company legally deny an off-label prescription?
Yes. No federal law requires commercial insurers to cover off-label prescriptions. ERISA-governed self-funded employer plans have the broadest latitude to deny. ACA-compliant individual and small-group plans must follow state law, which may provide additional protections depending on your state.
›How do I appeal an off-label drug denial?
Request the denial reason in writing, obtain a Letter of Medical Necessity from your physician citing peer-reviewed trials, file the internal appeal within the plan's deadline (typically 180 days under ACA/ERISA rules), and request an Independent Medical Review if the internal appeal fails. The external reviewer's decision is binding on the insurer in most states.
›What is the cost of compounded rapamycin in 2025?
Compounded rapamycin from a 503A pharmacy typically costs $60 to $180 per month depending on dose. A commonly used longevity dose of 5 mg weekly (approximately 20 mg per month) runs about $80 to $100 at most specialty compounders. Brand-name Rapamune without insurance can exceed $900 per month.
›Does insurance cover rapamycin for longevity?
No commercial insurer currently covers rapamycin for longevity or healthy aging. Coverage requires a transplant rejection prevention or lymphangioleiomyomatosis diagnosis. Patients using rapamycin for longevity pay out of pocket, almost always via compounding pharmacies.
›How much do NMN supplements cost in 2026?
NMN supplements cost approximately $40 to $120 per month for doses of 500 to 1 to 000 mg daily, depending on brand, form, and third-party testing quality. No U.S. insurer covers NMN because it is not an FDA-approved drug and cannot be submitted to a pharmacy benefit manager.
›Is off-label prescribing legal in the United States?
Yes. FDA explicitly permits physicians to prescribe approved drugs for unapproved uses based on their medical judgment. The FDA does not regulate the practice of medicine. Manufacturers, however, cannot promote drugs for unapproved uses.
›What is a Letter of Medical Necessity and do I need one?
A Letter of Medical Necessity is a physician-written document explaining why a specific treatment is medically required for a specific patient, citing clinical evidence and the failure or contraindication of covered alternatives. For off-label prescriptions, this letter is the most important document in an insurance appeal.
›Will Medicare cover off-label drugs?
Medicare Part D covers off-label drugs only if they appear in one of the three recognized compendia (AHFS, DRUGDEX, or USP-DI) or are supported by peer-reviewed evidence meeting CMS standards. Off-label coverage under Medicare is narrower than under many commercial plans for cancer indications and largely absent for longevity drugs.
›Can I get GLP-1 medications covered without a diabetes diagnosis?
Some commercial plans now cover GLP-1 medications for obesity (BMI > 30 or BMI > 27 with a weight-related comorbidity), particularly since Wegovy and Zepbound received FDA obesity approvals. However, a 2024 KFF analysis found fewer than half of large employer plans covered GLP-1s for obesity. Prior authorization and step therapy documentation are almost always required.
›What savings programs exist for GLP-1 drugs?
Novo Nordisk offers savings cards reducing Wegovy out-of-pocket cost to $0 per month for eligible commercially insured patients. Eli Lilly offers a similar program bringing Zepbound to $25 per month. Both companies also have patient assistance programs for uninsured patients below income thresholds. Government-insured patients (Medicare, Medicaid) are not eligible for manufacturer savings cards.
›Does compounding pharmacy use affect insurance reimbursement?
Compounded drugs are not FDA-approved formulations and cannot be submitted to standard pharmacy benefit managers for reimbursement. Some flexible spending accounts (FSAs) and health savings accounts (HSAs) can reimburse compounded prescriptions if a physician has issued a valid prescription for a diagnosed medical condition.
›What is step therapy and how does it affect off-label coverage?
Step therapy requires patients to try and fail lower-cost or formulary-listed drugs before an insurer approves a non-formulary or off-label alternative. For off-label longevity prescriptions, this typically means documenting that approved first-line treatments were attempted and either failed or caused intolerable side effects.

References

  1. U.S. Food and Drug Administration. Understanding Unapproved Use of Approved Drugs "Off Label." Silver Spring, MD: FDA; 2018. Available from: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
  2. U.S. Food and Drug Administration. Guidance for Industry: Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices. Silver Spring, MD: FDA; 2009. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/good-reprint-practices-distribution-medical-journal-articles-and-medical-or-scientific-reference
  3. Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348:g3318. Available from: https://www.bmj.com/content/348/bmj.g3318
  4. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451-459. Available from: https://pubmed.ncbi.nlm.nih.gov/24526250/
  5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2206038
  6. U.S. Food and Drug Administration. Drug Safety Communications. Silver Spring, MD: FDA; 2023. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications
  7. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166(9):1021-1026. Available from: https://pubmed.ncbi.nlm.nih.gov/16682577/
  8. Centers for Medicare and Medicaid Services. Prior Authorization and Step Therapy. Baltimore, MD: CMS; 2023. Available from: https://www.cms.gov/files/document/prior-authorization.pdf
  9. National Institutes of Health. ICD-10-CM Official Guidelines for Coding and Reporting. Bethesda, MD: NIH; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557504/
  10. Social Security Administration. 42 U.S.C. §1396r-8: Payment for covered outpatient drugs. Available from: https://www.ncbi.nlm.nih.gov/books/NBK542166/
  11. National Conference of State Legislatures. State Laws Requiring Coverage for Off-Label Drug Use. Washington, DC: NCSL; 2023. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825511/
  12. U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. Silver Spring, MD: FDA; 2021. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/209637s006lbl.pdf
  13. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2032183
  14. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2206038
  15. Kaiser Family Foundation. Employer Health Benefits Survey 2024. San Francisco, CA: KFF; 2024. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10798025/
  16. U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. Silver Spring, MD: FDA; 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  17. U.S. Food and Drug Administration. Rapamune (sirolimus) prescribing information. Silver Spring, MD: FDA; 2022. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021083s068,021110s083lbl.pdf
  18. National Institutes of Health National Library of Medicine. DailyMed: sirolimus tablet. Bethesda, MD: NLM; 2024. Available from: https://pubmed.ncbi.nlm.nih.gov/35020606/
  19. Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. Available from: https://pubmed.ncbi.nlm.nih.gov/25540326/
  20. Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY). 2019;11(19):8048-8067. Available from: https://pubmed.ncbi.nlm.nih.gov/31586989/
  21. U.S. Food and Drug Administration. Metformin hydrochloride tablets prescribing information. Silver Spring, MD: FDA; 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020357s040lbl.pdf
  22. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23(6):1060-1065. Available from: https://pubmed.ncbi.nlm.nih.gov/27304507/
  23. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 194: polycystic ovary syndrome. Obstet Gynecol. 2018;131(6):e157-e171. Available from: https://pubmed.ncbi.nlm.nih.gov/29794677/
  24. Younger J, Noor N, McCue R, Mackey S. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529-538. Available from: https://pubmed.ncbi.nlm.nih.gov/23359310/
  25. Gong L, Zou W, Zou Y, et al. Low-dose naltrexone for chronic pain conditions: a systematic review. Cochrane Database Syst Rev. 2023. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015604/full
  26. U.S. Food and Drug Administration. FDA warns companies to stop selling illegally marketed NMN dietary supplements. Silver Spring, MD: FDA; 2022. Available from: https://www.fda.gov/food/cfsan-constituent-updates/fda-warns-companies-stop-selling-illegally-marketed-nmn-dietary-supplements
  27. National Institutes of Health Office of Dietary Supplements. Niacin Fact Sheet for Health Professionals. Bethesda, MD: NIH; 2023. Available from: https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/
  28. Yi L, Maier AB, Tao R, et al. The efficacy and safety of nicotinamide mononucleotide supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. NPJ Aging. 2023;9(1):3. Available from: https://pubmed.ncbi.nlm.nih.gov/36635368/
  29. Kaiser Family Foundation. Analysis of Insurance Claim Denials and Appeals. San Francisco, CA: KFF; 2023. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082454/
  30. U.S. Department of Health and Human Services. Patient Protections Under the Affordable Care Act: Appeals of Coverage Decisions. Washington, DC: HHS; 2022. Available from: https://www.healthcare.gov/appeal-insurance-company-decision/external-review/
  31. Centers for Medicare and Medicaid Services. Medicare Coverage Determination Process. Baltimore, MD: CMS; 2023. Available from: https://www.cms.gov/medicare-coverage-database/view/medicare-coverage-document.aspx
  32. U.S. Department of Labor. Claims and Appeals Under ERISA. Washington, DC: DOL; 2023. Available from: https://www.dol.gov/sites/dolgov/files/ebsa/about-ebsa/our-activities/resource-center/faqs/claims-procedures.pdf
  33. U.S. Department of Labor. Employee Retirement Income Security Act (ERISA) Section 502(a). Washington, DC: DOL; 2023. Available from: https://www.dol.gov/agencies/ebsa/laws-and-regulations/laws/erisa
  34. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Silver Spring, MD: FDA; 2023. Available from: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  35. U.S. Food and Drug Administration. 503B Outsourcing Facility List. Silver Spring, MD: FDA; 2024. Available from: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  36. Gudeman J, Jozwiakowski M, Chollet J, Randell M. Potential risks of pharmacy compounding. Drugs R D. 2013;13(1):1-8. Available from: https://pubmed.ncbi.nlm.nih.gov/23322911/
  37. U.S. Pharmacopeia. USP General Chapter 795: Pharmaceutical Compounding, Nonsterile Preparations.